Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 6, 2007, Pages 863-869

  Kim, Jong Gwang ^a   Sohn, Sang Kyun ^a   Song, Hong Suk ^b   Kwon, Ki Young ^b   Do, Young Rok ^b   Lee, Kyung Hee ^c   Hyun, Myung Soo ^c   Ryoo, Hun Mo ^d   Bae, Sung Hwa ^d   Park, Keon Uk ^e   Baek, Jin Ho ^e   Lee, Won Sik ^f   Chung, Joo Seop ^g   Cho, Goon Jae ^g   Sohn, Chang Hak ^h   Jang, Jung Soon ⁱ   Chung, Ho Young ^a   Yu, Wansik ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Dongsan Medical Center   (South Korea)

^c Young Nam University Hospital   (South Korea)

^d Catholic University of Daegu   (South Korea)

^e Dongguk University College of Medicine   (South Korea)

^f Daegu Fatima Hospital   (South Korea)

^g Pusan National University Hospital   (South Korea)

^h Inje University   (South Korea)

ⁱ Gyeongsang National University   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Gastric cancer; Paclitaxel

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; FEMALE; FEVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; NEUTROPENIA; PACLITAXEL; RECURRENCE; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 34548555620     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0433-8     Document Type: Article

References (26)

1. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18-29
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Ransch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41
3. Pyrhonen S, Kuitunen T, Kouri M (1995) A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer. Br J Cancer 71:587-591
4. Glimelius B, Hoffmann K, Haglund U, Nyron O, Sjoden PO (1994) Initial or delayed chemotherapy with best supportive in advanced gastric cancer. Ann Oncol 5:189-190
5. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3818
6. Vanhoefer U, Wagner T, Lutz M, Van Cutsem E, Nordlinger B, Reuse S, Baron B, Wilke H, Wils J (2001) Randomized phase II study of weekly 24-h infusion of high dose 5-FU ± folinic acid (HD-FU ± FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953. Eur J Cancer 37:27
7. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Hermann R, Honegger H, Cavalli F, Alberto P, Castighine M, Goldhirsch A (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 11:301-306
8. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-323
9. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667
10. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825
11. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
12. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF (1998) Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4:269-274
13. Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, Kollmannsberger C, Kanz L (1997) A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 8:396-399
14. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempd V, Uemens M, Kanz L, Bokemeyer C (2000) A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83:458-462
15. Kim MK, Lee KH, Hyun MS, Do YR, Song HS, Lee WS, Park KU, Baek JH, Kim JG (2005) A multi-center, phase II clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. Cancer Res Treat 37:349-353
16. Georgiadis MS, Russell EK, Gazdar AF, Johnson BE (1997) Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res 3:449-454
17. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68:1104-1109
18. Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T (1997) Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother Pharmacol 40:245-250
19. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR (2003) Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480-2486
20. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361
21. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel- refractory ovarian cancer. J Clin Oncol 20:2365-2369
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan JS, Rubinstein L, Verweij J, Van Glabbeke M, Van Qosterom At, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
23. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
24. Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK (2004) A multi-center, late phase II clinical trial of genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 12:1059-1064
25. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS (1999) Paclitaxel, 5-flourouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85:295-301
26. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C (2002) Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 13:497-503